
    
      A randomized, double-blind, parallel-controlled, multicenter phase 3 clinical trial.

      560 patients with non-resectable locally advanced, metastatic or recurrent non-squamous cell
      non-small cell lung cancer (NSCLC) were randomly divided into two groups (SCT510 group and
      bevacizumab group) at a 1:1 ratio, and the treatment included combination chemotherapy and
      maintenance treatment, followed by follow-up.
    
  